Primary biliary cirrhosis
|
0.330 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.
|
21399635 |
2011 |
Primary biliary cirrhosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
Among 21 non-HLA susceptibility loci for PBC identified in GWASs of individuals of European descent, three loci (IL7R, IKZF3, and CD80) showed significant associations (combined p = 3.66 × 10(-8), 3.66 × 10(-9), and 3.04 × 10(-9), respectively) and STAT4 and NFKB1 loci showed suggestive association with PBC (combined p = 1.11 × 10(-6) and 1.42 × 10(-7), respectively) in the Japanese population.
|
23000144 |
2012 |
Primary biliary cirrhosis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
This is the first study to demonstrate that POGLUT1 and not CD80 is the effector gene regulated by the primary functional SNP rs2293370, and that increased expression of POGLUT1 might be involved in the pathogenesis of PBC.
|
30643196 |
2019 |
Primary biliary cirrhosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
Because activated T cells target the intrahepatic bile ducts in PBC and pre-clinical models suggested that blocking CD80/CD86 with CTLA-4 Ig might have therapeutic benefit in PBC, we performed an open-label trial to determine if CTLA-4 Ig (abatacept) is safe and potentially efficacious in PBC patients with an incomplete response to UDCA.
|
31027870 |
2019 |
Celiac Disease
|
0.310 |
Biomarker
|
disease |
BEFREE |
CD80 (B7-1) and CD86 (B7-2) genes and genetic susceptibility to coeliac disease.
|
12121279 |
2002 |
Celiac Disease
|
0.310 |
Biomarker
|
disease |
CTD_human |
Multiple common variants for celiac disease influencing immune gene expression.
|
20190752 |
2010 |
Biliary cirrhosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.
|
21399635 |
2011 |
Vitiligo
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo.
|
22561518 |
2012 |
Secondary Biliary Cholangitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.
|
21399635 |
2011 |
Biliary Cirrhosis, Primary, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.
|
21399635 |
2011 |
Glioma
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
In contrast to CD80 (B7.1) and CD86 (B7.2), ICOSL protein and mRNA was expressed in 7 of 12 glioma cell lines.
|
14603470 |
2003 |
Glioma
|
0.220 |
Biomarker
|
disease |
RGD |
Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells.
|
10078962 |
1999 |
Glioma
|
0.220 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effects of BB-102-based vaccine on glioma in vivo.
|
24408016 |
2014 |
Experimental Autoimmune Encephalomyelitis
|
0.200 |
Biomarker
|
disease |
RGD |
Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model.
|
9379015 |
1997 |
Adult T-Cell Lymphoma/Leukemia
|
0.200 |
Biomarker
|
disease |
RGD |
Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade.
|
10590132 |
2000 |
Kidney Failure
|
0.200 |
Biomarker
|
disease |
RGD |
Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue.
|
16893502 |
2006 |
Malignant Glioma
|
0.200 |
Biomarker
|
disease |
RGD |
Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells.
|
10078962 |
1999 |
Anti-Basement Membrane Glomerulonephritis
|
0.200 |
Biomarker
|
disease |
RGD |
CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis.
|
10712436 |
2000 |
Lupus Erythematosus, Systemic
|
0.150 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians.
|
23273568 |
2013 |
Lupus Erythematosus, Systemic
|
0.150 |
Biomarker
|
disease |
BEFREE |
Here we investigated whether selective blockade of CD28-CD80/86 co-stimulatory interactions abrogates lupus nephritis development in a murine model of SLE.
|
28631301 |
2017 |
Lupus Erythematosus, Systemic
|
0.150 |
Biomarker
|
disease |
BEFREE |
The data showed 4E5 function and suggested that blockade of CD80/CD28 co-stimulatory signal pathway with 4E5 is a promising strategy to decelerate the progression of lupus-like disease and other autoimmune diseases.
|
21978690 |
2011 |
Lupus Erythematosus, Systemic
|
0.150 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations.
|
25862617 |
2016 |
Lupus Erythematosus, Systemic
|
0.150 |
GeneticVariation
|
disease |
GWASDB |
Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians.
|
23273568 |
2013 |
Lupus Erythematosus, Systemic
|
0.150 |
Biomarker
|
disease |
BEFREE |
Furthermore, the ratio of CD86/CD80 is higher in SLE patients compared with healthy donors.
|
20067533 |
2009 |
Lupus Erythematosus, Systemic
|
0.150 |
GeneticVariation
|
disease |
BEFREE |
Single nuclear polymorphism rs2222631 was found associated with SLE with genome-wide significance (P_all=4.5E-08, OR=0.86) and is independent of rs6804441 in CD80, whose association was reported previously.
|
25862617 |
2016 |